The low-density lipoprotein test market size has grown strongly in recent years. It will grow from $8.83 billion in 2025 to $9.32 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, early clinical reliance on ldl-c testing, rising incidence of obesity and diabetes, expansion of hospital-based diagnostic laboratories, growing awareness of cholesterol management.
The low-density lipoprotein test market size is expected to see strong growth in the next few years. It will grow to $11.47 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing focus on preventive healthcare, rising screening for dyslipidaemia, expanding use of advanced lipid testing methods, growing demand for early stroke and heart disease risk detection, higher healthcare spending on diagnostics. Major trends in the forecast period include rising emphasis on preventive cardiovascular screening, growing use of comprehensive lipid panel testing, increasing demand for routine cholesterol monitoring, expansion of ldl testing in metabolic disorders, rising adoption of point-of-care lipid testing.
The increasing prevalence of cardiovascular diseases is anticipated to drive the growth of the low-density lipoprotein test market in the coming years. Cardiovascular diseases are conditions that affect the heart or blood vessels. The LDL test helps manage cardiovascular diseases by directly measuring low-density lipoprotein levels in the blood. For example, in February 2024, according to the UK Parliament, a UK-based governing body, heart and circulatory diseases accounted for approximately 25% of all deaths in England, leading to over 140,000 fatalities annually and around 480 deaths each day, or one death every three minutes. Consequently, the rise in cardiovascular disease prevalence is fueling the growth of the low-density lipoprotein test market.
Major companies operating in the low-density lipoprotein (LDL) test market are emphasizing the development of innovative diagnostic solutions such as advanced lipoprotein analysis systems to enhance cardiovascular risk evaluation, diagnostic precision, and patient care. Advanced lipoprotein analysis systems employ technologies like nuclear magnetic resonance (NMR) spectroscopy and algorithm-driven interpretation to offer more comprehensive insights into lipid profiles beyond standard LDL-C measurements, supporting improved clinical decision-making for individuals with cardiometabolic risks. For example, in July 2023, Numares Health, a Germany-based health diagnostics company, launched the AXINON LDL-p Test System. This FDA-cleared diagnostic tool provides a more detailed evaluation of lipoproteins, delivering information on cardiac function beyond conventional LDL-C measurements. By utilizing nuclear magnetic resonance (NMR) spectroscopy, the system integrates advanced diagnostic algorithms to increase accuracy. It assists physicians in better managing patients at elevated risk of cardiovascular disease, particularly those with cardiometabolic risk factors.
In February 2023, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, acquired CinCor Pharma Inc. for an undisclosed amount. Through this acquisition, AstraZeneca is expected to strengthen its cardiorenal pipeline and expand it with Baxdrostat, a novel aldosterone synthase inhibitor (ASI). CinCor Pharma Inc. is a US-based clinical-stage biotechnology company that develops therapies to lower LDL and manage hypertension.
Major companies operating in the low-density lipoprotein test market are Abbott Laboratories, Siemens Healthineers, F Hoffmann La Roche Ltd, Danaher Corporation, Thermo Fisher Scientific Inc, Bio Rad Laboratories Inc, DiaSorin SpA, Randox Laboratories Ltd, Sekisui Diagnostics, DiaSys Diagnostic Systems GmbH, Eurolyser Diagnostica GmbH, Diazyme Laboratories Inc, OPKO Health Inc, Merck KGaA, Agilent Technologies Inc, Becton Dickinson and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Eurofins Scientific SE, Home Access Health Corporation.
North America was the largest region in the Low-Density Lipoprotein Test market in 2025. The regions covered in the low-density lipoprotein test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the low-density lipoprotein test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the low-density lipoprotein test market by increasing costs associated with imported diagnostic devices, reagents, and testing kits. These impacts are more pronounced across advanced ldl-p and ldl-b testing products, particularly in regions such as asia-pacific and europe that rely on global diagnostic supply chains. Hospitals and research laboratories face higher procurement and operational costs due to tariff pressures. However, tariffs have also encouraged local manufacturing of test kits, regional sourcing of reagents, and strengthened domestic diagnostic capabilities, supporting long-term market stability.
The low-density lipoprotein test market research report is one of a series of new reports that provides low-density lipoprotein test market statistics, including low-density lipoprotein test industry global market size, regional shares, competitors with a low-density lipoprotein test market share, detailed low-density lipoprotein test market segments, market trends and opportunities, and any further data you may need to thrive in the low-density lipoprotein test industry. This low-density lipoprotein test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The low-density lipoprotein (LDL) test is a type of blood test that doctors use to measure the levels of LDL cholesterol in a patient’s bloodstream. LDL testing can evaluate LDL levels on their own or as part of a lipid panel test. Low-density lipoprotein is a buildup of cholesterol in the arteries that can increase the risk of heart attacks and strokes.
The main product types of low-density lipoprotein tests include LDL-C, LDL-P, LDL-B, and other variants. Low-density lipoprotein cholesterol (LDL-C) is known as bad cholesterol because it accumulates in the walls of blood vessels, raising the risk of health problems such as heart attacks or strokes. It is used to detect and quantify the amount of low-density lipoprotein cholesterol (LDL-C) in the blood. The components used include kits, reagents, devices, and other materials, which are applied in conditions such as diabetes, stroke, atherosclerosis, obesity, dyslipidemia, carotid artery disease, peripheral arterial disease, angina, and others. The distribution channels include direct tenders and retail, which are utilized by hospitals, clinics, ambulatory care centers, research laboratories, and other facilities.
The low-density lipoprotein test market includes revenues earned by entities by measuring very low-density lipoprotein (VLDL) testing and ultra low-density lipoprotein (ULDL) testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The low-density lipoprotein test market size is expected to see strong growth in the next few years. It will grow to $11.47 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing focus on preventive healthcare, rising screening for dyslipidaemia, expanding use of advanced lipid testing methods, growing demand for early stroke and heart disease risk detection, higher healthcare spending on diagnostics. Major trends in the forecast period include rising emphasis on preventive cardiovascular screening, growing use of comprehensive lipid panel testing, increasing demand for routine cholesterol monitoring, expansion of ldl testing in metabolic disorders, rising adoption of point-of-care lipid testing.
The increasing prevalence of cardiovascular diseases is anticipated to drive the growth of the low-density lipoprotein test market in the coming years. Cardiovascular diseases are conditions that affect the heart or blood vessels. The LDL test helps manage cardiovascular diseases by directly measuring low-density lipoprotein levels in the blood. For example, in February 2024, according to the UK Parliament, a UK-based governing body, heart and circulatory diseases accounted for approximately 25% of all deaths in England, leading to over 140,000 fatalities annually and around 480 deaths each day, or one death every three minutes. Consequently, the rise in cardiovascular disease prevalence is fueling the growth of the low-density lipoprotein test market.
Major companies operating in the low-density lipoprotein (LDL) test market are emphasizing the development of innovative diagnostic solutions such as advanced lipoprotein analysis systems to enhance cardiovascular risk evaluation, diagnostic precision, and patient care. Advanced lipoprotein analysis systems employ technologies like nuclear magnetic resonance (NMR) spectroscopy and algorithm-driven interpretation to offer more comprehensive insights into lipid profiles beyond standard LDL-C measurements, supporting improved clinical decision-making for individuals with cardiometabolic risks. For example, in July 2023, Numares Health, a Germany-based health diagnostics company, launched the AXINON LDL-p Test System. This FDA-cleared diagnostic tool provides a more detailed evaluation of lipoproteins, delivering information on cardiac function beyond conventional LDL-C measurements. By utilizing nuclear magnetic resonance (NMR) spectroscopy, the system integrates advanced diagnostic algorithms to increase accuracy. It assists physicians in better managing patients at elevated risk of cardiovascular disease, particularly those with cardiometabolic risk factors.
In February 2023, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, acquired CinCor Pharma Inc. for an undisclosed amount. Through this acquisition, AstraZeneca is expected to strengthen its cardiorenal pipeline and expand it with Baxdrostat, a novel aldosterone synthase inhibitor (ASI). CinCor Pharma Inc. is a US-based clinical-stage biotechnology company that develops therapies to lower LDL and manage hypertension.
Major companies operating in the low-density lipoprotein test market are Abbott Laboratories, Siemens Healthineers, F Hoffmann La Roche Ltd, Danaher Corporation, Thermo Fisher Scientific Inc, Bio Rad Laboratories Inc, DiaSorin SpA, Randox Laboratories Ltd, Sekisui Diagnostics, DiaSys Diagnostic Systems GmbH, Eurolyser Diagnostica GmbH, Diazyme Laboratories Inc, OPKO Health Inc, Merck KGaA, Agilent Technologies Inc, Becton Dickinson and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Eurofins Scientific SE, Home Access Health Corporation.
North America was the largest region in the Low-Density Lipoprotein Test market in 2025. The regions covered in the low-density lipoprotein test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the low-density lipoprotein test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the low-density lipoprotein test market by increasing costs associated with imported diagnostic devices, reagents, and testing kits. These impacts are more pronounced across advanced ldl-p and ldl-b testing products, particularly in regions such as asia-pacific and europe that rely on global diagnostic supply chains. Hospitals and research laboratories face higher procurement and operational costs due to tariff pressures. However, tariffs have also encouraged local manufacturing of test kits, regional sourcing of reagents, and strengthened domestic diagnostic capabilities, supporting long-term market stability.
The low-density lipoprotein test market research report is one of a series of new reports that provides low-density lipoprotein test market statistics, including low-density lipoprotein test industry global market size, regional shares, competitors with a low-density lipoprotein test market share, detailed low-density lipoprotein test market segments, market trends and opportunities, and any further data you may need to thrive in the low-density lipoprotein test industry. This low-density lipoprotein test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The low-density lipoprotein (LDL) test is a type of blood test that doctors use to measure the levels of LDL cholesterol in a patient’s bloodstream. LDL testing can evaluate LDL levels on their own or as part of a lipid panel test. Low-density lipoprotein is a buildup of cholesterol in the arteries that can increase the risk of heart attacks and strokes.
The main product types of low-density lipoprotein tests include LDL-C, LDL-P, LDL-B, and other variants. Low-density lipoprotein cholesterol (LDL-C) is known as bad cholesterol because it accumulates in the walls of blood vessels, raising the risk of health problems such as heart attacks or strokes. It is used to detect and quantify the amount of low-density lipoprotein cholesterol (LDL-C) in the blood. The components used include kits, reagents, devices, and other materials, which are applied in conditions such as diabetes, stroke, atherosclerosis, obesity, dyslipidemia, carotid artery disease, peripheral arterial disease, angina, and others. The distribution channels include direct tenders and retail, which are utilized by hospitals, clinics, ambulatory care centers, research laboratories, and other facilities.
The low-density lipoprotein test market includes revenues earned by entities by measuring very low-density lipoprotein (VLDL) testing and ultra low-density lipoprotein (ULDL) testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Low-Density Lipoprotein Test Market Characteristics
3. Low-Density Lipoprotein Test Market Supply Chain Analysis
4. Global Low-Density Lipoprotein Test Market Trends and Strategies
5. Low-Density Lipoprotein Test Market Analysis of End Use Industries
7. Global Low-Density Lipoprotein Test Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Low-Density Lipoprotein Test Total Addressable Market (TAM) Analysis for the Market
9. Low-Density Lipoprotein Test Market Segmentation
10. Low-Density Lipoprotein Test Market Regional and Country Analysis
11. Asia-Pacific Low-Density Lipoprotein Test Market
12. China Low-Density Lipoprotein Test Market
13. India Low-Density Lipoprotein Test Market
14. Japan Low-Density Lipoprotein Test Market
15. Australia Low-Density Lipoprotein Test Market
16. Indonesia Low-Density Lipoprotein Test Market
17. South Korea Low-Density Lipoprotein Test Market
18. Taiwan Low-Density Lipoprotein Test Market
19. South East Asia Low-Density Lipoprotein Test Market
20. Western Europe Low-Density Lipoprotein Test Market
21. UK Low-Density Lipoprotein Test Market
22. Germany Low-Density Lipoprotein Test Market
23. France Low-Density Lipoprotein Test Market
24. Italy Low-Density Lipoprotein Test Market
25. Spain Low-Density Lipoprotein Test Market
26. Eastern Europe Low-Density Lipoprotein Test Market
27. Russia Low-Density Lipoprotein Test Market
28. North America Low-Density Lipoprotein Test Market
29. USA Low-Density Lipoprotein Test Market
30. Canada Low-Density Lipoprotein Test Market
31. South America Low-Density Lipoprotein Test Market
32. Brazil Low-Density Lipoprotein Test Market
33. Middle East Low-Density Lipoprotein Test Market
34. Africa Low-Density Lipoprotein Test Market
36. Low-Density Lipoprotein Test Market Competitive Landscape and Company Profiles
37. Low-Density Lipoprotein Test Market Other Major and Innovative Companies
40. Low-Density Lipoprotein Test Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Low-Density Lipoprotein Test Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses low-density lipoprotein test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for low-density lipoprotein test? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The low-density lipoprotein test market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Low-Density Lipoprotein Cholesterol (LDL-C); Low-Density Lipoprotein Particle Number (LDL-P); Low-Density Lipoprotein Particle Size (LDL-B); Other Product Types2) By Component: Kits; Reagents; Devices; Other Components
3) By Disease Type: Diabetes; Stroke; Atherosclerosis; Obesity; Dyslipidaemia; Carotid Artery Disease; Peripheral Arterial Disease; Angina; Other Disease Types
4) By Distribution Channel: Direct Tenders; Retail
5) By End User: Hospitals; Clinics; Ambulatory Care; Research Laboratory; Other End Users
Subsegments:
1) By Low-Density Lipoprotein Cholesterol (LDL-C): Direct Measurement Tests; Calculated LDL-C Tests2) By Low-Density Lipoprotein Particle Number (LDL-P): NMR (Nuclear Magnetic Resonance) Tests; Other Particle Counting Methods
3) By Low-Density Lipoprotein Particle Size (LDL-B): Gradient Gel Electrophoresis; Other Size Measurement Techniques
4) By Other Product Types: Lipid Panel Tests: Genetic Testing For Dyslipidemia; Point-Of-Care Testing Devices
Companies Mentioned: Abbott Laboratories; Siemens Healthineers; F Hoffmann La Roche Ltd; Danaher Corporation; Thermo Fisher Scientific Inc; Bio Rad Laboratories Inc; DiaSorin SpA; Randox Laboratories Ltd; Sekisui Diagnostics; DiaSys Diagnostic Systems GmbH; Eurolyser Diagnostica GmbH; Diazyme Laboratories Inc; OPKO Health Inc; Merck KGaA; Agilent Technologies Inc; Becton Dickinson and Company; Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; Eurofins Scientific SE; Home Access Health Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Low-Density Lipoprotein Test market report include:- Abbott Laboratories
- Siemens Healthineers
- F Hoffmann La Roche Ltd
- Danaher Corporation
- Thermo Fisher Scientific Inc
- Bio Rad Laboratories Inc
- DiaSorin SpA
- Randox Laboratories Ltd
- Sekisui Diagnostics
- DiaSys Diagnostic Systems GmbH
- Eurolyser Diagnostica GmbH
- Diazyme Laboratories Inc
- OPKO Health Inc
- Merck KGaA
- Agilent Technologies Inc
- Becton Dickinson and Company
- Quest Diagnostics Incorporated
- Laboratory Corporation of America Holdings
- Eurofins Scientific SE
- Home Access Health Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 9.32 Billion |
| Forecasted Market Value ( USD | $ 11.47 Billion |
| Compound Annual Growth Rate | 5.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
